EPO Patents = 4

Forward Citations = 13

Loading Chart...

10 inventors (with patents filed for the assignee):

Thomas Kirkegaard Jensen (8 out of 14 patents)

Anders Mørkeberg Hinsby (4 out of 5 patents)

Marja Helena Jaattela (3 out of 8 patents)

4. Gert Mads Bolwig (2 out of 2 patents)

5. Carlos Roberto Camozzi (2 out of 3 patents)

6. Catherine Kolster Fog-Tonnesen (1 out of 1 patent)

7. Nikolaj Havnsøe Torp Petersen (1 out of 1 patent)

8. Claus Bornæs (1 out of 1 patent)

9. Elina Ikonen (1 out of 1 patent)

10. Burcin Gungor (1 out of 1 patent)

11. Cathrine Kolster Fog-TØNNESEN (0 patent)

8 patents: Sort by Forward Citations

1. 11304941 - Use of HSP70 as a regulator of enzymatic activity (2022-04-19),

2. 11253505 - Arimoclomol for treating glucocerebrosidase associated disorders (2022-02-22),

3. 11229633 - Arimoclomol formulation (2022-01-25),

4. 11045460 - Use of Hsp70 as a regulator of enzymatic activity (2021-06-29),

5. 10898476 - Heat shock proteins and cholesterol homeostasis (2021-01-26),

6. 10709700 - Arimoclomol formulation (2020-07-14),

7. 10543204 - Use of Hsp70 as a regulator of enzymatic activity (2020-01-28),

8. 10532085 - Methods for increasing intracellular activity of Hsp70 (2020-01-14),

Orphazyme A/S is a biopharmaceutical company dedicated to developing treatments for patients living with rare neurodegenerative diseases. The company's lead candidate, arimoclomol, is currently in clinical trials for several rare diseases. Orphazyme is focused on bringing innovative therapies to market to improve the lives of patients and their families.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

8 Patents

#39 in Copenhagen

#324 in Denmark

Copenhagen, Denmark

Orphazyme A/s